(How) can we prevent type 2 diabetes?

被引:36
作者
Buchanan, Thomas A. [1 ]
机构
[1] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90089 USA
关键词
D O I
10.2337/db07-0140
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is a progressive disease. It develops over years as a result of declining pancreatic β-cell compensation for chronic and often worsening insulin resistance. Preventing type 2 diabetes requires modification of the underlying disease biology to slow, stop, or reverse the decline in β-cell compensation. Data from six randomized trials reveal several interventions that reduce the number of high-risk people who develop diabetes during relatively short periods of treatment. Interventions that reduce body fat or that mitigate the effect of excess fat to cause insulin resistance provide the greatest risk reduction and the best evidence for real disease modification. At least two studies indicate that disease modification is possible soon after glucose levels enter the diabetes range. These findings, combined with the fact that falling β-cell compensation leads to rising glycemia, provide a rationale for an intervention strategy that begins with lifestyle modification and progresses to pharmacological therapy aimed at reducing insulin resistance if lifestyle approaches fail to prevent glucose from rising to the diabetes range. Our knowledge base in this field is still quite rudimentary, and we have no information about truly long-term (i.e., for decades) prevention of type 2 diabetes. Even for the short to intermediate term, additional work is needed to determine optimal application of the general strategy described above, to examine combination approaches to prevention, and to test new interventions as they become available. Such work should focus on disease modification, not just cases of diabetes, as a major outcome. © 2007 by the American Diabetes Association.
引用
收藏
页码:1502 / 1507
页数:6
相关论文
共 21 条
[1]  
Bosch J, 2006, NEW ENGL J MED, V355, P1551
[2]   Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women [J].
Buchanan, TA ;
Xiang, AH ;
Peters, RK ;
Kjos, SL ;
Marroquin, A ;
Goico, J ;
Ochoa, C ;
Tan, S ;
Berkowitz, K ;
Hodis, HN ;
Azen, SP .
DIABETES, 2002, 51 (09) :2796-2803
[3]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[4]  
Diabetes Prevention Progam, 2005, DIABETES, V54, P1150
[5]   β-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes:: A new analysis [J].
Ferrannini, E ;
Gastaldelli, A ;
Miyazaki, Y ;
Matsuda, M ;
Mari, A ;
DeFronzo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (01) :493-500
[6]   The natural course of β-cell function in nondiabetic and diabetic individuals -: The insulin resistance atherosclerosis study [J].
Festa, A ;
Williams, K ;
D'Agostino, R ;
Wagenknecht, LE ;
Haffner, SM .
DIABETES, 2006, 55 (04) :1114-1120
[7]   Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial [J].
Gerstein, H. C. ;
Yusuf, S. ;
Holman, R. R. ;
Bosch, J. ;
Anand, S. ;
Avezum, A. ;
Budaj, A. ;
Chiasson, J. ;
Conget, I. ;
Dagenais, G. ;
Davis, M. ;
Diaz, R. ;
Dinccag, N. ;
Enjalbert, M. ;
Escalante, A. ;
Fodor, G. ;
Hanefeld, M. ;
Hedner, T. ;
Jolly, K. ;
Keltai, M. ;
Laakso, M. ;
Lanas, F. ;
Lonn, E. ;
McQueen, M. ;
Mohan, V. ;
Phillips, A. ;
Piegas, L. ;
Pirags, V. ;
Probstfield, J. ;
Shaw, J. ;
Schmid, I. ;
Teo, K. ;
Zimmet, P. ;
Zinman, B. ;
Gerstein, H. C. ;
Yusuf, S. ;
Bosch, J. ;
Pogue, J. ;
Sheridan, P. ;
Dinccag, N. ;
Hanefeld, M. ;
Hoogwerf, B. ;
Laakso, M. ;
Mohan, V. ;
Shaw, J. ;
Zinman, B. ;
Holman, R. R. ;
Diaz, R. ;
Ahuad Guerrero, R. ;
Albisu, J. .
LANCET, 2006, 368 (9541) :1096-1105
[8]   Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease [J].
Goldfine, AB ;
Bouche, C ;
Parker, RA ;
Kim, C ;
Kerivan, A ;
Soeldner, JS ;
Martin, BC ;
Warram, JH ;
Kahn, CR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) :2724-2729
[9]  
Group DPPR., 2002, N Engl J Med, V346, P393, DOI [DOI 10.1056/NEJMOA012512, 10.1056/NEJMoa012512]
[10]   Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance [J].
Haffner, SM ;
Miettinen, H ;
Gaskill, SP ;
Stern, MP .
DIABETOLOGIA, 1996, 39 (10) :1201-1207